Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Viatris Inc.

Vertex vs Viatris: A Decade of Cost Efficiency

__timestampVertex Pharmaceuticals IncorporatedViatris Inc.
Wednesday, January 1, 2014609870004050200000
Thursday, January 1, 20151255420005047100000
Friday, January 1, 20162104600006078400000
Sunday, January 1, 20172751190006931500000
Monday, January 1, 20184095390006861900000
Tuesday, January 1, 20195477580007056300000
Wednesday, January 1, 20207363000008149300000
Friday, January 1, 202190420000012310800000
Saturday, January 1, 202210803000009765700000
Sunday, January 1, 202312622000008988300000
Monday, January 1, 20241530500000
Loading chart...

Data in motion

Cost of Revenue Efficiency: A Tale of Two Giants

In the competitive landscape of pharmaceuticals, cost efficiency is paramount. Vertex Pharmaceuticals Incorporated and Viatris Inc. have been pivotal players, each with distinct strategies. From 2014 to 2023, Vertex's cost of revenue surged by over 1,900%, reflecting its aggressive expansion and investment in innovative treatments. In contrast, Viatris, formed in 2020, maintained a relatively stable cost structure, peaking in 2021 with a 30% increase from 2020, before a gradual decline.

A Decade of Financial Dynamics

Vertex's cost efficiency improved significantly, with costs rising from $61 million in 2014 to $1.26 billion in 2023. Meanwhile, Viatris, despite its higher baseline, showcased a strategic cost reduction from $12.31 billion in 2021 to $8.99 billion in 2023. This comparison highlights the diverse approaches in managing operational costs, offering insights into their financial health and strategic priorities.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025